The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insur Regulatory News (SBRE)

Share Price Information for Sabre Insur (SBRE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 162.80
Bid: 162.80
Ask: 163.20
Change: -2.40 (-1.45%)
Spread: 0.40 (0.246%)
Open: 167.00
High: 167.00
Low: 162.80
Prev. Close: 165.20
SBRE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

11 Oct 2018 07:00

RNS Number : 6525D
Sabre Insurance Group PLC
11 October 2018
 

11 October 2018

 

SABRE INSURANCE GROUP PLC

Trading Update

Sabre Insurance Group plc (the "Group", or "Sabre"), one of the UK's leading private motor insurance underwriters, today provides a trading update for the nine months ending 30 September 2018.

Summary

· The Group continues its strategy of focusing on underwriting profitability over growth

· Superior underwriting performance, underpinned by strong claims experience in the period under review, supports the Group's continued expectation of delivering a FY 2018 combined ratio better than our mid-70%'s target and slightly higher than the FY 2017 combined ratio, which was 68.5%

· Strong organic capital generation supports the potential for an attractive full-year dividend with a solvency coverage ratio of 195%(1) as at the end of September, above our 140% - 160% target range

· Appropriate pricing actions taken to cover anticipated claims inflation, with GWP for the first nine months of the year remaining broadly flat year on year at £162.6m(1) (2017: £165.0m). The Group maintains its expectations for FY 2018 GWP to be in line with 2017

 

Geoff Carter, Chief Executive Officer, commented:

Throughout a period of strong competition in the UK motor insurance sector, we have continued to apply our core philosophy of focusing on underwriting profitability, with volume remaining an output rather than target.

As communicated earlier in the year, we have sought to cover anticipated claims inflation and will continue this focus throughout the rest of this year. Whilst premiums for Q3 2018 were slightly below a strong comparative period in Q3 2017, we remain confident that we will end the year with premium in-line with 2017.

Our absolute focus on profitability has yielded a strong underwriting result for the year to date and has allowed us to generate significant excess capital during the period under review. Having paid an interim dividend of 7.2 pence per share, the solvency capital ratio as at 30 September 2018 is at 195%, well above our target operating range of 140%-160%. This provides the Board the option to return surplus capital to shareholders following the full-year results, should the capital position improve further throughout the remainder of 2018. 

(1) Numerical information not subject to audit

 

 

Media enquiries

Tulchan Communications LLP

James Macey White, Roger Tejwani & David Ison

020 7353 4200

sabre@tulchangroup.com

 

Investor enquiries

Sabre Insurance Group plc

Adam Westwood

adam.westwood@sabre.co.uk

07776 649 119

 

LEI code: 2138006RXRQ8P8VKGV98

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFFUFISFASELS
Date   Source Headline
11th May 202311:42 amRNSDirector/PDMR Shareholding
18th Apr 20233:19 pmRNSDirector/PDMR Shareholding
12th Apr 202311:53 amRNSDirector/PDMR Shareholding
6th Apr 202312:28 pmRNSDirector/PDMR Shareholding
31st Mar 20233:43 pmRNSNotice of AGM
31st Mar 20233:37 pmRNSDirector/PDMR Shareholding
14th Mar 20237:00 amRNSFinal Results
13th Mar 202312:13 pmRNSDirector/PDMR Shareholding
13th Feb 20231:51 pmRNSDirector/PDMR Shareholding
13th Jan 20231:52 pmRNSHolding(s) in Company
11th Jan 20234:00 pmRNSDirector/PDMR Shareholding
19th Dec 20222:31 pmRNSHolding(s) in Company
13th Dec 20221:20 pmRNSDirector/PDMR Shareholding
11th Nov 202212:09 pmRNSDirector/PDMR Shareholding
7th Nov 20221:47 pmRNSHolding(s) in Company
13th Oct 20227:00 amRNSTrading Update
11th Oct 20223:20 pmRNSDirector/PDMR Shareholding
28th Sep 20222:11 pmRNSDirector/PDMR Shareholding
23rd Sep 202211:47 amRNSDirector/PDMR Shareholding
13th Sep 20223:57 pmRNSDirector/PDMR Shareholding
26th Aug 202210:45 amRNSDirectorate Change
11th Aug 20223:25 pmRNSDirector/PDMR Shareholding
10th Aug 20229:08 amRNSHolding(s) in Company
1st Aug 20229:19 amRNSDirector/PDMR Shareholding
28th Jul 20222:34 pmRNSHolding(s) in Company
28th Jul 20229:14 amRNSHolding(s) in Company
27th Jul 20221:35 pmRNSDirector/PDMR Shareholding
27th Jul 20229:26 amRNSHolding(s) in Company
27th Jul 20229:19 amRNSDirector/PDMR Shareholding
26th Jul 202212:19 pmRNSDirector/PDMR Shareholding
26th Jul 202212:06 pmRNSDirector/PDMR Shareholding
26th Jul 20227:00 amRNSHalf-Year Report 2022
18th Jul 20221:07 pmRNSHolding(s) in Company
14th Jul 20227:00 amRNSHalf-Year 2022 Trading Update
12th Jul 202212:49 pmRNSDirector/PDMR Shareholding
1st Jul 20229:55 amRNSHolding(s) in Company
14th Jun 202211:58 amRNSDirector/PDMR Shareholding
13th Jun 20223:54 pmRNSDirector/PDMR Shareholding
6th Jun 20223:15 pmRNSDirector/PDMR Shareholding
6th Jun 20223:06 pmRNSDirector/PDMR Shareholding
25th May 20221:24 pmRNSResult of AGM
25th May 20227:00 amRNSTrading Update
19th May 20221:45 pmRNSHolding(s) in Company
13th May 20222:24 pmRNSHolding(s) in Company
11th May 20222:27 pmRNSDirector/PDMR Shareholding
26th Apr 20223:17 pmRNSDirector/PDMR Shareholding
26th Apr 20222:21 pmRNSDirector/PDMR Shareholding
14th Apr 20229:01 amRNSHolding(s) in Company
13th Apr 20224:18 pmRNSNotice of AGM
12th Apr 20223:34 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.